Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

Preclinical IPOs have yet to perform as well as top clinical success stories, but that hasn’t curbed interest

July 25, 2020 1:46 AM UTC

An analysis of preclinical IPO performance since the window opened eight years ago shows the companies have done about as well as their clinical peers. What’s missing are standout examples of explosive growth, though those could be around the corner as the cutting-edge technologies driving some of the excitement begin to mature.

The willingness of buysiders to invest in preclinical companies is a relatively recent phenomenon. Only 55 preclinical biotechs have gone public on NASDAQ, with 50 of those offerings occurring since 2013, according to BioCentury’s BCIQ database...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article